EGFR and non-small cell lung carcinoma: An intracranial PDX murine model revealed profoundtumor regression on oral dosing with 9 suggesting thisnovel compound as a potential lead in the treatment of localized andCNS metastatic NSCLC driven by activating mutant bearing EGFR andfor osimertinib-resistant EGFR+ NSCLC bearing the C797S resistancemutation profile (L858R/C797S and exon19del/C797S).